There is nothing more critical right now than doing what we can to accelerate potential vaccines, diagnostics, and treatments for COVID-19. We’ve rapidly shifted our entire platform towards COVID-19 response, committing $25M of free access to our infrastructure to projects that can support R&D across a range of applications.
I’m thrilled to announce today that as part of that offer, we will be supporting Moderna with process optimization for key raw materials used in the manufacturing of its mRNA vaccines, including mRNA-1273, Moderna’s vaccine candidate against COVID-19, the first to enter clinical trials. With access to our high throughput automated tools for biological engineering, we hope that we can help Moderna accelerate its plans to improve the efficiency of its upstream manufacturing process. You can read more about Moderna’s vaccine efforts here.
We’re eager to support many more efforts in COVID-19, through DNA synthesis, full genome sequencing of SARS-CoV-2 for epidemiological tracking, scaling of diagnostics, antibody lead optimization, and antigen design for serological testing, vaccine, or therapeutic development, among others. If you have a project that you think we can help accelerate with our platform, please reach out to firstname.lastname@example.org.